Abstracts tagged "cardiovascular disease and morbidity and mortality"

Abstract Number: 1089 • 2019 ACR/ARP Annual Meeting
Causes of Death in ANCA-Associated Vasculitis According to ANCA Type
Zachary Wallace¹, Xiaoqing Fu ¹, Tyler Harkness ¹, John Stone ², Yuqing Zhang ³ and Hyon K. Choi ³, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Survival has improved in ANCA-associated vasculitis (AAV) with evolving management strategies, but patients remain at an increased risk of death compared to the general…
Abstract Number: 1619 • 2019 ACR/ARP Annual Meeting
Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study
Viola Signorini¹, Dina Zucchi ², Chiara Tani ³, Rosa Maria Bruno ⁴, Elena Elefante ³, Chiara Stagnaro ⁵, Linda Carli ³, Alice Parma ³, Francesco Ferro ⁶, Sabina Armenia ⁷, lorenzo Ghiadoni ⁸, Stefano Taddei ⁷ and Marta Mosca ³, ¹Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Toscana, Italy, ²Rheumatology Unit. Department of clinical and experimental medicine, University of PIsa, Pisa, Toscana, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Hypertension Unit, Department of clinical e experimental medicine, University di Pisa, Pisa, Italy, ⁵Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁷Hypertension Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy, ⁸Emergency Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy
Background/Purpose: Systemic Lupus Erithematosus (SLE) is associated with increased cardiovascular (CV) risk compared with general population; an accelerated atherosclerosis is considered the main underlying mechanism.…
Abstract Number: 26 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study
Joong Kyong Ahn¹, Jiwon Hwang², Hyemin Jeong³, Ji Young Chae⁴, Hyungjin Kim³, Hoon-Suk Cha³ and Eun-Mi Koh³, ¹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of
Background/Purpose: Several studies have reported increased overall mortality in association with rheumatoid factor (RF) in RA. However, the clinical significance including health outcomes of RF…
Abstract Number: 1066 • 2015 ACR/ARHP Annual Meeting
Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations
Narender Annapureddy¹, Achint Patel², Rabi Yacoub³, Krishna Pakanati⁴, Shiv Agarwal⁵, Priya Simoes⁶, Sunil Kamat⁷, Alexandre Benjo⁸ and Girish Nadkarni⁹, ¹Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ²Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Gateway Medical Center, Clarksville, TN, ⁵Cardiology, University of Arkansas Medical Sciences, Little Rock, AR, ⁶Internal Medicine, St.Lukes Roosevelt Hospital Center at Mount Sinai, New York, NY, ⁷Critical Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India, ⁸Ochsner Clinic Foundation, New Orleans, NY, ⁹Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Cardiovascular disease remains the most common cause of mortality in Systemic lupus erythematosus (SLE). Some studies suggest that mortality due to acute myocardial infarction…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].